The adult central nervous system (CNS) has a very limited intrinsic ability to regenerate after injury. Traumatic brain injuries or neurodegenerative diseases cause neuronal cell leads to long-lasting functional impairments. The profound effect observed from these injuries results from a series of events that occurs immediately following injury and persists for several weeks. These events take place not only at the intrinsic level via intracellular signaling pathways but at the extrinsic level as well. Recent evidence indicates that in order to promote significant regeneration in the damaged CNS, a combinatorial approach addressing both the intrinsic and extrinsic barriers to regeneration is necessary. Our goal is to understand how modification of the post-injury microenvironment will affect nerve regeneration. Specifically, our hypothesis is that transplantation of neural progenitor cells (NPCs) into the retina combined with administration of an epidermal growth factor receptor (EGFR) inhibitor via an engineered construct will enhance nerve regeneration in an optic nerve axotomy model. This hypothesis is based on two observations: (1) NPCs can differentiate into neurons and incorporate into existing neural networks, and (2) administration of EGFR inhibitors to damaged optic nerve and spinal cord result in regeneration of injured neurons. We will use an optic nerve crush injury model to determine the effectiveness of our treatment. At the site of injury, we will implant a polymer construct allowing controlled delivery of the EGFR inhibitor, followed by injection of NPCs into the vitreous of the eye.
Our specific aims are to: (1) develop and characterize a drug delivery system for the controlled release of the EGFR inhibitor, (2) develop and characterize a construct for in vivo delivery of the inhibitor at the injury site, and (3) assess the effects of a combinatorial treatment approach on nerve regeneration in vivo in an optic nerve injury model. Combinatorial treatments provide a promising new option for therapy in CNS repair. We believe this approach in conjunction with cell transplantation therapy will provide important information regarding nerve regeneration in the mature >CNS. Accomplishing the specific aims outlined will provide an understanding of nerve regeneration and the glial scar microenvironment in vivo. Relevance: The central nervous system has very limited repair capabilities. This limitation is due to neuronal cell death and a post-injury cellular environment that is not favorable to regrowth of nerves. A combinatorial treatment of transplantation of neural progenitor cells and administration of an epidermal growth factor inhibitor can address both of these factors simultaneously, thus providing a new avenue for therapy.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
5F31EY019441-02
Application #
7752538
Study Section
Special Emphasis Panel (ZRG1-ETTN-T (29))
Program Officer
Steinmetz, Michael A
Project Start
2009-01-01
Project End
2010-09-30
Budget Start
2010-01-01
Budget End
2010-09-30
Support Year
2
Fiscal Year
2010
Total Cost
$40,368
Indirect Cost
Name
Yale University
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Hertz, Jonathan; Robinson, Rebecca; Valenzuela, Daniel A et al. (2013) A tunable synthetic hydrogel system for culture of retinal ganglion cells and amacrine cells. Acta Biomater 9:7622-9
Robinson, Rebecca; Viviano, Stephen R; Criscione, Jason M et al. (2011) Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: the role of size for intraocular drug delivery. ACS Nano 5:4392-400
Robinson, Rebecca; Bertram, James P; Reiter, Jill L et al. (2010) New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres. J Microencapsul 27:263-71